Humanized anti-CD38 mAbs, currently available for the treatment of MM, include intravenous daratumumab (DARA) [25,26,27,28,29,30,31,32,33,34,35,36,37], subcutaneous DARA [75], and isatuximab [38,39,40,41,42,43,44] (Figure 1). Here, CD38 is linked to Miyoshi myopathy.